Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +2.18%77 Interest Coverage is 34.01 as of Mar. 2026, which is 24% below its 10-year median of 44.62. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 463 Medical Devices & Instruments companies, Getein Biotech ranks better than 58.32% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Getein Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was ¥84 Mil. Getein Biotech's Interest Expense for the
three
months ended in Mar. 2026 was ¥-2 Mil.
Getein Biotech's interest coverage for the quarter that ended in Mar. 2026 was 34.01.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Getein Biotech's Interest Coverage or its related term are showing as below:
SHSE:603387'
s Interest Coverage Range Over the Past 10 Years
Min: 15.83 Med: 44.62 Max: 2727.54
Current: 24.6
SHSE:603387's Interest Coverage is ranked better than 58.32% of 463
companies
in the Medical Devices & Instruments industry
Industry Median: 16.24
vs SHSE:603387: 24.60
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Getein Biotech Interest Coverage Related Terms
Getein Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Getein Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SHSE:603387 vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, Getein Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a Interest Coverage of 34.01 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Getein Biotech and its competitors. This is 24% below median its historical median of 44.62. Over the past decade, Getein Biotech's Interest Coverage has ranged from 15.83 to 2,727.54. According to the industry distribution chart, Getein Biotech ranks #193 out of 463 companies in the Medical Devices & Instruments industry, placing it in the top 41.7%.
Is Getein Biotech's Interest Coverage too high?
Getein Biotech's current Interest Coverage of 34.01 is 24% below median its 10-year median of 44.62. Over the past 10 years, this metric has ranged from a low of 15.83 to a high of 2,727.54. The Medical Devices & Instruments industry median Interest Coverage is 16.24. Getein Biotech's value of 34.01 is 109.4% above this industry median. Based on the distribution chart, Getein Biotech ranks #193 out of 463 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #193 out of 463 companies for Interest Coverage. This puts Getein Biotech in the upper half of its industry. The industry median Interest Coverage is 16.24. Getein Biotech's value of 34.01 is 109.4% above this benchmark. Historically, Getein Biotech's own Interest Coverage has ranged from 15.83 to 2,727.54 over the past decade. While the company's 10-year median is 44.62 vs. the industry median of 16.24, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.24, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current Interest Coverage of 34.01 is 109.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current Interest Coverage is 34.01, which is 24% below median its own 10-year median of 44.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.90 — trading 17.6% above its estimated fair value. The current Interest Coverage is 34.01, which is 24% below median its 10-year median of 44.62 and 109.4% above the Medical Devices & Instruments industry median of 16.24. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Interest Coverage is 34.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.90 is trading 17.6% above its estimated GF Value™ of ¥7.57.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Interest Coverage: 34.01 (24% below median its 10-year median of 44.62)
GF Value™: ¥7.57 vs. price of ¥8.90 (17.6% above fair value)
Industry Position: 109.4% above the Medical Devices & Instruments median (#193 of 463)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
